BeOne Medicines (ONC) Receivables (2017 - 2026)

BeOne Medicines (ONC) has 10 years of Receivables data on file, last reported at $938.0 million in Q1 2026.

• Quarterly Receivables rose 30.78% year-over-year to $938.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $938.0 million (up 30.78% YoY) and the FY2025 annual result came in at $865.1 million, up 27.92% from the prior year.
• Receivables rose to $938.0 million in Q1 2026 per ONC's latest filing, from $865.1 million in the prior quarter.
• Across five years, Receivables topped out at $938.0 million in Q1 2026 and bottomed at $174.9 million in Q2 2022.
• The 5-year median for Receivables is $435.3 million (2024), against an average of $493.3 million.
• Peak annual rise in Receivables reached 125.44% in 2022, while the deepest fall reached 63.9% in 2022.
• Tracing ONC's Receivables over 5 years: stood at $176.2 million in 2022, then soared by 104.17% to $359.8 million in 2023, then surged by 87.98% to $676.3 million in 2024, then gained by 27.92% to $865.1 million in 2025, then increased by 8.43% to $938.0 million in 2026.
• Per Business Quant, the three latest ONC Receivables figures stand at $938.0 million (Q1 2026), $865.1 million (Q4 2025), and $863.3 million (Q3 2025).

Peer Comparison